Clal Biotechnology Industries Ltd. (TASE: CBI)
Health Care · Biotechnology · IL
₪0.24
+0.41% today · -20.4% 1Y
Clal Biotechnology Industries Ltd. (TASE: CBI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $12.70M and employs 121 people.
Over the last twelve months the share price has lost 20.4%, trading between 0.23 and 0.44.
Tweenvest scores Clal Biotechnology Industries Ltd. across four factors: quality 47/100, value 52/100. Its strongest factor is value.
CBI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.70M
- Revenue (TTM)
- $-39.61K
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- 0.35
- 52-week high
- ₪0.44
- 52-week low
- ₪0.23
- Avg volume (3M)
- —
- Shares outstanding
- 156.85M
- Employees
- 121
- Next earnings
- —
About Clal Biotechnology Industries Ltd.
Clal Biotechnology Industries Ltd. (CBI) operates as a venture capital and private equity firm, primarily funding innovative companies within the life sciences, medical device, biopharmaceutical, and broader biotechnology sectors. The firm is adept at investing across a comprehensive spectrum of development stages, ranging from initial incubation, seed, and startup phases, through early, emerging, mid, and late-stage ventures, including pre-clinical development, PIPEs, and growth capital financing. CBI strategically targets companies based in the United States and Israel, typically deploying between $0.5 million and $10 million into each investment. It frequently assumes the role of a lead investor and a significant shareholder, often securing a board seat within its portfolio companies. Established in July 1998, CBI utilizes the personal capital of its management team for its investments. Its primary base is in Tel Aviv, Israel, complemented by an additional office in Cambridge, Massachusetts. The firm formerly functioned as a subsidiary of Clal Industries and Investments Ltd.
- ISIN
- IL0011042806
- Founded
- 1998
- Listed since
- Jun 4, 2007
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $260.95 | -1.82% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.16 | -0.02% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.22 | -0.29% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.30 | -1.23% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $147.72 | -6.99% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.